CLINICAL TRIALS PROFILE FOR RESIQUIMOD

Clinical Trials for Resiquimod

Trial ID	Title	Status	Sponsor	Phase	Summary
NCT00114920 ↗	Twelve Week Safety and Efficacy Study With a Topical Gel to Treat Common Warts in Adults	Completed	Graceway Pharmaceuticals, LLC	Phase 2	The primary purpose of this study is to evaluate the effectiveness in adults, of four different strengths of resiquimod gel applied to common wart(s) three times a week for twelve weeks. A second purpose is to evaluate the safety of the drug.
NCT00115141 ↗	Four Week Safety and Efficacy Study With a Topical Gel to Treat Common Warts in Adults	Completed	Graceway Pharmaceuticals, LLC	Phase 2	The primary purpose of this study is to evaluate the effectiveness in adults, of four different strengths of resiquimod gel applied to common wart(s) three times a week for four weeks. A second purpose is to evaluate the safety of the drug.
NCT00116662 ↗	An up to Twelve Week Safety and Efficacy Study With a Topical Gel to Treat Common Warts in Pediatric Subjects	Completed	Graceway Pharmaceuticals, LLC	Phase 2	The primary purpose of this study is to evaluate the effectiveness in pediatric subjects of three different strengths of resiquimod gel applied to common wart(s) three times a week for up to twelve weeks. A second purpose is to evaluate the safety of the drug.
NCT00116675 ↗	Four Week Safety and Efficacy Study With a Topical Gel to Treat Common Warts in Pediatric Subjects	Completed	Graceway Pharmaceuticals, LLC	Phase 2	The primary purpose of this study is to evaluate the effectiveness in pediatric subjects of three different strengths of resiquimod gel applied to common wart(s) three times a week for four weeks. A second purpose is to evaluate the safety of the drug.
NCT00117871 ↗	Study With a Topical Gel to Treat Common Warts in Adults	Completed	Graceway Pharmaceuticals, LLC	Phase 2	The primary purpose of this study is to evaluate the effectiveness in adults of 2 different strengths of resiquimod gel applied to common wart(s) five times a week for up to 12 weeks. A second purpose is to evaluate the safety of the drug.
NCT00117923 ↗	Study With a Topical Gel to Treat Common Warts in Adults	Completed	Graceway Pharmaceuticals, LLC	Phase 2	The primary purpose of this study is to evaluate the effectiveness in adults of four different strengths of resiquimod gel applied to common wart(s) five times a week for four weeks. A second purpose is to evaluate the safety of the drug.

Clinical Trial Conditions for Resiquimod

Condition Name

Condition Name
Intervention	Trials
Warts	6
Locally Advanced Solid Tumor	1
Stage IIB Melanoma	1
Malignant Melanoma	1

Condition MeSH

Condition MeSH
Intervention	Trials
Warts	6
Melanoma	4
Influenza, Human	2
Carcinoma, Basal Cell	1

Clinical Trial Locations for Resiquimod

Trials by Country

Trials by Country
Location	Trials
United States	30
Switzerland	2
Germany	2
Australia	1
Hong Kong	1

Trials by US State

Trials by US State
Location	Trials
Minnesota	3
Utah	2
Missouri	2
Arkansas	2
Indiana	2

Clinical Trial Progress for Resiquimod

Clinical Trial Phase

Clinical Trial Phase
Clinical Trial Phase	Trials
Phase 2	8
Phase 1/Phase 2	4
Phase 1	2

Clinical Trial Status

Clinical Trial Status
Clinical Trial Phase	Trials
Completed	14
Withdrawn	1
Recruiting	1

Clinical Trial Sponsors for Resiquimod

Sponsor Name

Sponsor Name
Sponsor	Trials
Graceway Pharmaceuticals, LLC	6
Spirig Pharma Ltd.	2
National Cancer Institute (NCI)	2

Sponsor Type

Sponsor Type
Sponsor	Trials
Industry	9
Other	9
NIH	2